Oestrogen-related receptor alpha inverse agonist XCT-790 arrests A549 lung cancer cell population growth by inducing mitochondrial reactive oxygen species production.
OBJECTIVE
Although oestrogen-related receptor alpha (ERRalpha) is primarily thought to regulate energy homeostasis, it also serves as a prognostic marker for cancer. The aim of this study was to investigate any connection between ERRalpha activity and cell population growth.


METHODS
XCT-790, an ERRa specific inverse agonist, was employed to suppress ERRa activity in human non-small cell lung cancer cells (NSCLC) A549. Gene expressions were detected using quantitative real-time PCR and Western blot analysis. Mitochondrial mass, membrane potential and reactive oxygen species (ROS) production were measured by staining with Mitotracker green, JC-1 and CM-H(2)DCFDA dyes respectively. Rate of progression through the tricarboxylic acid (TCA) cycle was analysed by measuring activities of citrate synthase and succinate dehydrogenase. Cell cycle analysis was performed by using flow cytometry.


RESULTS
We found that XCT-790 treatment reduced mitochondrial mass but enhanced mitochondrial ROS production by increasing rate through the TCA cycle, elevating mitochondrial membrane potential (DeltaPsi(m)) and down-regulating expression of superoxide dismutase. It was further demonstrated that XCT-790-induced ROS modulated p53 and Rb signalling pathways and suppressed cell replication.


CONCLUSIONS
ERRalpha affects cell cycle mechanisms through modulating mitochondrial mass and function. Dysregulation of this essential pathway leads to elevation in mitochondrial ROS production, which in turn modulates activities of tumour suppressors, resulting in cell cycle arrest.
Wang
J
J
Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Wang
Y
Y
Wong
C
C
D001562:Benzimidazoles / Q000378:metabolism; D002232:Carbocyanines / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D005456:Fluorescent Dyes / Q000378:metabolism; D006801:Humans; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D008564:Membrane Potentials / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects; D009570:Nitriles / Q000494:pharmacology*; D017382:Reactive Oxygen Species / Q000032:analysis / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000819:agonists*; D015398:Signal Transduction / Q000187:drug effects; D013482:Superoxide Dismutase / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology*; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D000097983:ERRalpha Estrogen-Related Receptor
D001562:Benzimidazoles; D002232:Carbocyanines; D005456:Fluorescent Dyes; D009570:Nitriles; D017382:Reactive Oxygen Species; D011960:Receptors, Estrogen; D013482:Superoxide Dismutase; D013844:Thiazoles; D016159:Tumor Suppressor Protein p53; D000097983:ERRalpha Estrogen-Related Receptor; C488234:XCT790; C068624:5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine
Nat Rev Cancer. 2007 Jan;7(1):46-53
17186017
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15400-5
17881568
Cancer Res. 2008 Nov 1;68(21):8805-12
18974123
Cell Signal. 2007 Oct;19(10):2088-97
17644309
Cell Metab. 2007 May;5(5):345-56
17488637
Cell Metab. 2007 Jan;5(1):35-46
17189205
J Clin Endocrinol Metab. 2005 Mar;90(3):1830-44
15598686
Diabetes. 2004 Feb;53 Suppl 1:S130-5
14749278
Mol Cell Biol. 2004 Oct;24(20):9079-91
15456881
Circulation. 2005 Oct 25;112(17):2686-95
16246967
Cancer Res. 2002 Nov 15;62(22):6510-8
12438245
J Biol Chem. 2002 Jul 5;277(27):24826-34
11986328
J Clin Oncol. 2005 May 1;23(13):2980-7
15860853
J Biol Chem. 2002 Aug 30;277(35):31679-93
12077144
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7111-6
12764228
FEBS Lett. 2009 Feb 18;583(4):643-7
19171140
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8466-71
12832613
Oncogene. 2008 Sep 11;27(40):5303-14
18521084
Mol Cancer Ther. 2009 Mar;8(3):672-81
19276159
Biochem Biophys Res Commun. 2007 May 25;357(1):231-6
17418099
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6472-7
15087503
Eur J Cancer. 2005 Jul;41(10):1487-94
15949936
Curr Mol Med. 2007 Sep;7(6):532-40
17896990
J Biol Chem. 2003 Mar 14;278(11):9013-8
12522104
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12146-50
8618861
J Invest Dermatol. 2002 Sep;119(3):576-82
12230498
J Biol Chem. 2006 Dec 29;281(52):39897-906
17079227
J Cell Biochem. 2005 Nov 1;96(4):760-74
16149072
J Med Chem. 2004 Nov 4;47(23):5593-6
15509154
PLoS One. 2007 Aug 01;2(8):e693
17668070
Cancer Res. 2007 Sep 1;67(17):8388-95
17804755
J Cell Mol Med. 2009 Sep;13(9B):3051-60
18544047
Mol Cell Biol. 2005 Dec;25(24):10684-94
16314495
Cell. 2006 Oct 20;127(2):397-408
17055439
Cancer Res. 1999 Sep 15;59(18):4519-24
10493499
Cancer Cell. 2006 Sep;10(3):241-52
16959615
Curr Cancer Drug Targets. 2007 Sep;7(6):591-604
17896924
Endocr Rev. 1999 Oct;20(5):689-725
10529899
J Biol Chem. 2007 Sep 28;282(39):28328-28334
17631492
Mol Cell Biol. 2001 Apr;21(8):2743-54
11283254
J Mol Med (Berl). 2005 Jun;83(6):457-67
15770498
Cancer Res. 2001 Sep 15;61(18):6755-61
11559547
Genes Dev. 2001 Apr 1;15(7):833-8
11297507
Biomarkers. 2005 Jul-Aug;10(4):295-309
16240504
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6570-5
15100410
Cancer Res. 2004 Jul 1;64(13):4670-6
15231680